Gene expression alterations in brains of mice infected with three strains of scrapie by Skinner, Pamela J et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
BMC Genomics
Open Access Research article
Gene expression alterations in brains of mice infected with three 
strains of scrapie
Pamela J Skinner*1, Hayet Abbassi1, Bruce Chesebro2, Richard E Race2, 
Cavan Reilly3 and Ashley T Haase4
Address: 1Department of Veterinary and Biomedical Sciences, University of Minnesota, USA, 2NIH Laboratory of Persistent Viral Diseases, Rocky 
Mountain Laboratories, Hamilton, Montana, USA, 3Department of Biostatistics, University of Minnesota, USA and 4Department of Microbiology, 
University of Minnesota, USA
Email: Pamela J Skinner* - skinn002@umn.edu; Hayet Abbassi - abbas004@umn.edu; Bruce Chesebro - BCHESEBRO@niaid.nih.gov; 
Richard E Race - RRACE@niaid.nih.gov; Cavan Reilly - reill017@umn.edu; Ashley T Haase - haase001@umn.edu
* Corresponding author    
Abstract
Background:  Transmissible spongiform encephalopathies (TSEs) or prion diseases are fatal
neurodegenerative disorders which occur in humans and various animal species. Examples include
Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle,
chronic wasting disease (CWD) in deer and elk, and scrapie in sheep, and experimental mice. To
gain insights into TSE pathogenesis, we made and used cDNA microarrays to identify disease-
associated alterations in gene expression. Brain gene expression in scrapie-infected mice was
compared to mock-infected mice at pre-symptomatic and symptomatic time points. Three strains
of mouse scrapie that show striking differences in neuropathology were studied: ME7, 22L, and
Chandler/RML.
Results: In symptomatic mice, over 400 significant gene expression alterations were identified. In
contrast, only 22 genes showed significant alteration in the pre-symptomatic animals. We also
identified genes that showed significant differences in alterations in gene expression between
strains. Genes identified in this study encode proteins that are involved in many cellular processes
including protein folding, endosome/lysosome function, immunity, synapse function, metal ion
binding, calcium regulation and cytoskeletal function.
Conclusion: These studies shed light on the complex molecular events that occur during prion
disease, and identify genes whose further study may yield new insights into strain specific
neuropathogenesis and ante-mortem tests for TSEs.
Background
Transmissible spongiform encephalopathies (TSEs) or
prion diseases are fatal neurodegenerative disorders
which occur in humans and various animal species.
Examples include Creutzfeldt-Jakob disease (CJD) in
humans, bovine spongiform encephalopathy (BSE) in
cattle, chronic wasting disease (CWD) in deer and elk, and
scrapie in sheep, goats and experimental mice [1]. TSEs
are characterized by vacuolation of the neuropil, neuron
loss, activation of astrocytes and microglia, and in some
situations, deposition of amyloid fibrils [2,3]. While the
misfolded partially protease resistant isoform of endog-
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enous prion protein, also known as PrPsc or PrP-res [4,5],
is thought to play a critical role in these neuropathological
changes, the molecular mechanisms underlying the neu-
ropathology are far from clear [6,7].
With the goal of gaining insight into the basis of vacuoli-
zation and other neuropathological changes we under-
took microarray studies in three mouse scrapie strains
which differ in the neuropathological changes they
induce. Here, we report the results of this investigation of
mouse scrapie strains ME7, 22L, and RML-Chandler using
cDNA microarrays. While some of these differentially-
expressed genes have been described previously by others
in related TSE systems [8-28], our studies extend gene pro-
filing to include an important mouse scrapie strain, 22L
[29], and in addition identify many new genes of poten-
tial importance in scrapie neuropathogenesis.
Results and discussion
Microarray analysis of scrapie-infected mice at two times 
post-infection
Gene expression in six scrapie-infected mice was com-
pared to gene expression in two mock-infected mice at
104 and 146 days post-infection (dpi) using cDNA micro-
arrays. Of the six scrapie-infected mice, two were infected
with strain ME7, two with strain 22L, and two with strain
RML-Chandler. Day 104 was selected because it represents
a time post-infection in which no clinical symptoms were
observed and little neuropathology has been reported;
and day 146 was selected because it was the time point
empirically determined when the scrapie-infected mice
showed clinical symptoms. In order to optimize data col-
lected from microarrays hybridized with alternately fluo-
rescently labeled cDNA from scrapie and mock-infected
mice, we scanned each microarray at multiple laser set-
tings ranging from relatively low power to high power.
Resultant data collected for each spot on the hybridized
microarrays was plotted on a graph, with values from
scrapie infected samples on one axis, and values from
mock-infected mice on the other axis. For each of the indi-
vidual laser scans from each microarray, we found the
data output when viewed as a scatter plot was highly var-
iable, as exemplified in Figure 1. Only microarrays that
showed a scatter plot of spot values from scrapie vs. mock
with a slope of approximately one were considered for
subsequent analysis. The reasoning for this selection is
based on the assumption that most genes were not altered
in the scrapie-infected animals, and thus for most genes
spotted on the microarrays, fluorescently labeled cDNA
from scrapie-infected mice would show hybridization
equal to that of the fluorescently labeled cDNA from
mock-infected mice. This selection process helped reduce
artifacts from the microarray scanning process. As an addi-
tional means to optimize results, we also separately ana-
lyzed data from hybridized microarrays that were scanned
with relatively high and relatively low laser power in order
to best capture brightly and weakly stained spots, respec-
tively. Further, each microarray contained two copies of
Different scans of the same hybridized microarray show different results Figure 1
Different scans of the same hybridized microarray show different results. The representative hybridization results 
shown are from an ME7 infected mouse compared to a mock infected mouse. A) and B) show two scatter plots from two dif-
ferent scans of the same hybridized microarray. In each scatter plot, spot values from the mock infected animal are plotted on 
the X-axis and spots from scrapie infected animal are plotted on the Y-axis. Note that the scatter plots are different, and that 
in A) the spots more closely align with on the slope of 1 compared to the spots in B). The data from the scan presented in A) 
but not B) was used in these analyses.BMC Genomics 2006, 7:114 http://www.biomedcentral.com/1471-2164/7/114
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Table 1: Genes with known function altered at 146 dpi with q ≤ 5% and ≥ 1.5 fold change
Scan ID Name SAM q ME7 22L RML Ave Citations
Endocytosis or Lysosomal function
L H A AI838658 cathepsin B* 4 1 1.4 1.7 1.3 1.5 9 13
L H A AI845967 cathepsin S* 15 1 2.6 3.0 2.4 2.7 9 12 11 14 18
L H A AI838302 Cd63 antigen 5 1 1.3 1.7 1.4 1.4
L AI854206 hexosaminidase B* 4 1 1.9 1.8 1.4 1.7 9 11
H AI841188 legumain 2 3 1.0 1.5 1.3 1.3
H A AI850263 lysosomal membrane glycoprotein 2 2 3 1.0 1.6 1.2 1.2 9
L A AI845968 protective protein for beta-galactosidase 5 1 1.2 1.5 1.5 1.4 9
H A AI852375 sortilin 1* -3 1 -1.2 -1.5 -1.1 -1.3
L H A AI841326 transferrin* 4 1 1.1 1.6 1.6 1.4 9 22 20 23
Other proteases/protease inhibitors
L SSHI-1h6 cathepsin Z 2 4 1.5 1.1 1.5 1.4 12 11
L H A AI835498 cystatin C* 7 1 1.6 1.7 1.6 1.6 9 8
H A AI842540 transmem. Pr. with EGF-like and 2 follistatin-like domains 1 -3 1 -1.5 -1.1 -1.3 -1.3
Protein folding
L H A AI848744 heat shock protein 1, beta -3 1 -1.0 -1.2 -1.5 -1.2
L A AI844835 peptidylprolyl isomerase B 3 1 -1.1 1.6 1.6 1.3
Immunity
L H A AI848245 beta-2 microglobulin* 10 1 2.6 2.9 2.2 2.6 10 9 20 12 11
L H A AI836786 complement component 1 q alpha* 6 1 1.4 1.8 1.9 1.7 1 8 12 11
L H A AI854126 complement component 1, q beta* 4 1 2.2 1.6 1.6 1.8 1 8 12 11
H AI853826 Fms interacting protein -2 5 -1.2 -1.7 -1.4 -1.4
H A AI841111 lymphocyte antigen 6 complex, locus E* 2 3 1.0 1.6 1.2 1.3
Calcium regulation
L AI834839 calcium channel voltage-dependent T alpha1H 3 1 1.3 1.4 1.6 1.4
L H A AI835341 calmodulin 1 -4 1 -1.2 -1.3 -1.5 -1.3
L H A AI835663 calponin 3, acidic 3 1 1.7 1.4 1.1 1.4 9 11
L H A AI853527 copine VIII 3 1 1.4 1.2 1.6 1.4
H A AI847702 inositol 1,4,5-triphosphate receptor 1 -3 1 -1.2 -1.5 -1.2 -1.3
H A AI839585 visinin-like 1 -3 2 -1.5 -1.2 -1.3 -1.3
Cytoskeleton
L AI841156 actin related protein 2/3 complex, subunit 1A 3 1 1.0 1.4 1.6 1.3
H A AI846176 capping protein (actin filament) muscle Z-line, beta 3 1 1.3 2.3 1.1 1.5
L H A AI836096 glial fibrillary acidic protein 6 1 4 . 91 24 . 36 . 3 11 8 41 25 26 
27 19 17
L A AI849905 neurofilament 3, medium -3 1 -1.3 -1.6 -1.3 -1.4 10
L H A AI845192 peripherin 1 4 1 1.2 1.6 1.2 1.3
H AI845991 RIKEN cDNA 4930488L10 gene -2 4 -1.6 1.0 -1.2 -1.2
L H A AI845820 vimentin 6 1 2.2 2.6 1.4 2.0 10 9 8 19 11
Pumps or channels
L H A AI841308 ATPase, Na+/K+ transporting, beta 1 polypeptide -3 1 -1.6 -1.3 -1.2 -1.4
L H A AI836767 potassium inwardly-rectifying channel J 4 7 1 1.6 1.8 2.1 1.8
L H A AI839063 solute carrier family 25 (mitochondrial carrier), member 18 5 1 1.4 1.5 1.2 1.4 9
Lipid processing
L H A AI840024 apolipoprotein D* 8 1 1.5 2.6 2.3 2.1 9 12 17
L H A AI848248 apolipoprotein E* 8 1 1.9 1.8 2.0 1.9 9 18
Phosphatase or Kinase
H AI852186 ectonucleotide pyrophosphatase/phosphodiesterase 5* -2 5 -1.1 -1.6 -1.4 -1.4
H A AI841245 ethanolamine kinase 1 -2 5 -1.5 -1.1 -1.1 -1.2
H AI849290 mitogen activated protein kinase kinase 5 -2 4 -1.3 -1.3 -1.6 -1.4
H A AI842000 neurotrophic tyrosine kinase receptor type 2 3 2 1.1 1.9 1.3 1.4 9
H A AI848471 protein tyrosine phosphatase, receptor type, F -2 3 -1.1 -1.3 -1.5 -1.3
H AI854349 serum/glucocorticoid regulated kinase 2 4 1.6 1.2 1.0 1.2 9 12
L H A AI854038 sorbin and SH3 domain containing 1 3 1 1.6 1.3 1.0 1.3
Other enzymes
L H A AI851848 aldehyde dehydrogenase family 1, subfamily A1 4 1 1.2 1.7 1.5 1.5 10 9
H A AI838156 carbonic anhydrase 8 -2 3 -1.3 -1.7 1.0 -1.3 9
L H A AI839962 malate dehydrogenase 1, NAD (soluble) -3 1 -1.1 -1.5 -1.1 -1.2 9
Transcription or Translation
L AI840211 A kinase (PRKA) anchor protein 8-like 2 4 1.6 1.3 1.1 1.3
H AI835606 eukaryotic translation elongation factor 1 alpha 2 -2 3 -1.0 -1.1 -1.5 -1.2
H A AI853820 eukaryotic translation initiation factor 5A -3 1 -1.5 -1.3 -1.4 -1.4
L AI845998 GLI-Kruppel family member HKR2 2 5 1.6 1.3 -1.0 1.3
L AI847701 heterogeneous nuclear ribonucleoprotein D-like -3 5 -1.1 -1.8 -1.2 -1.3
L A AI845667 mitochondrial ribosomal protein L9 2 5 1.0 1.2 1.5 1.2
L A AI838178 myotrophin 3 1 -1.1 1.4 2.1 1.4BMC Genomics 2006, 7:114 http://www.biomedcentral.com/1471-2164/7/114
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A AI842636 phenylalanine-tRNA synthetase 1 (mitochondrial) -2 4 -1.5 -1.0 -1.2 -1.2
L A AI851649 ribosomal protein L12 3 1 1.1 1.2 1.5 1.2
H A AI854670 RIKEN cDNA A730098D12 gene -2 4 -1.1 -1.1 -1.5 -1.2
L A AI852411 SRY-box containing gene 9 3 1 -1.0 1.2 1.5 1.2 9
L A AI838500 TSPY-like 2 3 1 1.0 1.5 1.7 1.4
L AI854130 TSPY-like 4 -3 5 1.1 -1.3 -1.5 -1.2
Other
L H A AI854515 CD9 antigen 5 1 1.3 1.9 1.5 1.6 12 11
L H A AI836624 clusterin* 6 1 1.6 1.6 1.6 1.6 9 8 23 19 28
L H A AI841459 diazepam binding inhibitor 5 1 1.2 1.5 1.7 1.5 9
L H A AI854785 Endogenous retrovirus 3 1 2.0 1.2 1.9 1.6 21
H A AI843767 endosulfine alpha -2 5 -1.4 -1.3 -1.5 -1.4
L H A AI839644 ferritin light chain 1 5 1 1.4 1.2 1.6 1.4
A AI836826 glycoprotein 38* 2 4 1.2 1.6 1.4 1.4
L H A AI842053 lectin galactoside-binding sol. 3 binding prot.* 7 1 1.7 2.4 1.8 1.9 12 11
L H A AI841372 N-myc downstream regulated gene 4 -4 1 -1.1 -1.7 -1.3 -1.4
L AI854649 oxysterol binding protein 2 4 1.5 1.5 1.1 1.4
L AI837057 Septin 3 (Sept3), mRNA -3 5 1.0 -1.7 -1.4 -1.3
L AI845319 SPARC-like 1 3 1 1.0 1.3 1.5 1.3
L H A AI838871 synaptosomal-associated protein 25 -4 1 -1.5 -1.2 -1.3 -1.3 10 16
L H A AI854259 thyroid hormone receptor associated protein 2 -3 1 -1.1 -1.2 -1.5 -1.3
L H A AI841166 Ywhah -3 1 -1.2 -1.3 -1.5 -1.3
H AI854309 WD repeat domain, X-linked 1 -2 4 -1.0 -1.1 -2.1 -1.3
SAM Score (T-statistic), q (q-value %), Ave (average fold change for all three strains)
Scan (Scan(s) that showed gene with significant alteration in scrapie brain)
L, H, and A (Low, High, or Average of Low and High powered scans)
Expression values shown for scan and clone that showed the highest SAM score.
ID (GenBank # for BMAP clones. IDs that begin with SSHI are from Rashmi Korke's mouse cDNA library)
Struckthrough BMAP accession numbers indicate that our sequencing results did not match the published sequence for that clone.
IDs with struckthrough BMAP accession numbers are listed with the gene name that reflects our sequencing results.
*Genes with an asterisk encode extracellular proteins.
Table 2: Genes that showed significant alterations (q ≤ 5%) in brains of scrapie-infected mice at 104 dpi
Scan Clone ID Name SAM Score(d) q-value (%) Ave. FC
LA I 8 4 8 2 4 5 beta-2 microglobulin* 2.0 4.2 1.3
LA I 8 3 6 7 8 6 complement component 1 q alpha* 2.1 4.2 1.3
LA I 8 3 5 3 1 4 cyclin-dependent kinase 5, regulatory subunit (p35) 1.9 4.2 1.3
LA I 8 5 1 2 8 0 docking protein 4 1.8 4.2 1.2
LA I 8 5 4 7 8 5 endogenous retrovirus, Intracisternal A particles 1.8 4.2 1.2
L SSHI-2f6 endogenous retrovirus truncated gag 1.8 4.2 1.4
LA I 8 4 1 9 3 3 eukaryotic translation initiation factor 3, subunit 2 (beta) 1.8 4.2 1.2
LA I 8 3 6 0 9 6 glial fibrillary acidic protein 3.7 4.2 1.9
LA I 8 5 4 2 0 6 hexosaminidase B* 2.0 4.2 1.3
LA I 8 4 8 0 1 2 kinesin family member 3A 1.9 4.2 1.3
LA I 8 4 2 0 5 3 lectin, galactoside-binding, soluble, 3 binding protein* 1.9 4.2 1.2
LA I 8 4 9 1 2 7 unknown EST 2.0 4.2 1.3
LA I 8 5 4 9 0 5 unknown EST 1.9 4.2 1.3
LA I 8 5 3 7 1 9 unknown EST 1.8 4.2 1.3
L SSHII-1h12 not sequenced 1.8 4.2 1.2
LA I 8 4 0 0 6 6 Immunoglobulin superfamily, member 4B* 1.9 4.2 1.3
LA I 8 4 9 2 9 9 Protein tyrosine phosphatase, receptor type Z, polypeptide 1 1.8 4.2 1.2
LA I 8 5 1 5 9 4 RIKEN cDNA 1300010M03 gene 1.8 4.2 1.2
LA I 8 5 0 7 2 4 RIKEN cDNA 2400003C14 gene 2.3 4.2 1.3
LA I 8 4 3 1 9 3 RIKEN cDNA E130114P18 gene 2.2 4.2 1.3
LA I 8 4 0 4 4 1 secretogranin III* 1.9 4.2 1.2
LA I 8 4 6 0 4 8 RIKEN cDNA 2900073H19 gene 1.8 4.2 1.3
* Genes with an asterisk encode proteins that localize to extracellular space
Clone ID is GenBank # for BMAP clones. Clone IDs that begin with SSHI are from Rashmi Korke's mouse cDNA library
L stands for low scan
FC stands for fold change
Table 1: Genes with known function altered at 146 dpi with q ≤ 5% and ≥ 1.5 fold change (Continued)BMC Genomics 2006, 7:114 http://www.biomedcentral.com/1471-2164/7/114
Page 5 of 12
(page number not for citation purposes)
each gene so that for each hybridization, we obtained
results in duplicate. For each time point, the data from the
high, low, and averaged data sets were separately analyzed
using Significance Analysis of Microarrays (SAM) and pro-
duced unique data sets (indicated in Additional Data file
1, and Tables 1 and 2). These results demonstrate that
laser intensities used to scan DNA microarrays can dra-
matically affect resultant data collected. Furthermore,
these studies show that optimizing microarray scanning
conditions allows for the identification of significant dis-
ease-associated alterations in gene expression using mini-
mal numbers of mice.
Using this methodology, we identified over 400 genes
that showed significant alterations in expression in the six
scrapie infected mice compared to the two mock infected
mice at 146 dpi (Additional File 1). For brevity, the subset
of genes that have a known function and showed a fold
change equal to or higher than 1.5 for one or more strain
is presented in Table 1. Many of the identified genes have
previously been described in related TSE model systems
and are cited in Table 1 and Additional File 1.
Bioinformatic analyses, including literature searches, and
the Source [46], the National Center for Biotechnology
Information (NCBI), and the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) [30]
data base searches, were used to identify the function(s) of
each known gene identified in our study and group genes
by their influence on various cellular processes. Many of
the identified genes fell into more than one functional cat-
egory. For simplicity these genes are presented under a
single functional heading in Additional File 1 and Table 1.
Dominant groups of genes identified include those that
function in protein folding, endosome/lysosome func-
tion, immunity, the cytoskeleton, metal ion binding, cal-
cium regulation and synapse function.
Because we investigated total brain gene expression,
which amalgamates mRNA from all brain cell types
including neurons, glial, and endothelial cells, we antici-
pate that gene alterations that occur in a single cell type or
only in a particular region of the brain will show a low
fold change in this analysis due to dilution by mRNA from
surrounding cells or brain regions in which the particular
gene alteration is not occurring. Thus, for microarray anal-
yses involving complex tissues such as brain, low fold
changes in gene expression may indicate large fold
changes in a subset of cells or cells in a particular region
of the tissue and should not be overlooked.
We've included the presentation of Additional File 1,
which shows all significant alterations in gene expression
identified in the scrapie-infected mice compared to mock-
infected mice without a fold change filter applied (data
with a fold change filter is presented in Table 1). When we
filtered the data by fold change we lost the detection of
several genes whose alteration may have significant
impact on TSE disease pathogenesis or progression. For
example several genes that function in protein folding
showed a low but significant fold change and include:
Ahsa1, Dnajc1 Dnajc12, Dnajc4, Hspa12a, Hspca, Hspa4,
Hspa8, Vbp, and Ppia. Calmodulin 1 appeared as down
regulated in the data set filter by fold change, but the
unfiltered data set shows that calmodulin 2 and calmod-
ulin 3 were also down modulated. Given this, we propose
that it is important to consider genes that show significant
changes in expression with albeit low fold change.
Surprisingly, only 22 genes were identified as significantly
altered in the pre-symptomatic animals studied at 104
dpi. Six of the 22 genes were also identified as significantly
altered in the symptomatic animals. These included glial
fibrillary acidic protein (GFAP), complement component
C1qa, lectin galactoside-binding soluble 3 binding pro-
tein, beta-2 microglobulin, hexosaminidase B, and an
expressed sequence tag (EST) of unknown function. For
each of these genes the fold change was substantially
higher at 146 dpi compared to 104 dpi. Of the 22 genes,
only one, GFAP, showed an average fold change of at least
1.5 (Table 2). The dramatic difference in numbers of gene
expression alterations detected in the preclinical animals
compared to the animals in late stage of the disease sug-
gests that there is relatively little disruption in the brain
until the late stages of the disease, at which point there is
an abrupt massive disruption of multiple processes. Addi-
tional file 2 provides a visual representation of the micro-
array hybridization results for genes that showed
significant alteration and at least 1.5 fold change in the
scrapie infected mice.
Gene expression alterations that varied among strains
Mice infected intracerebrally with scrapie strains ME7, 22L
and RML-Chandler differ in incubation period and in
neuropathology [29,31,32]. To evaluate whether there
were alterations in gene expression that differed among
scrapie strains, and, if so, thereby identify genes that may
contribute to strain-specific neurodegenerative processes,
gene expression profiles for each strain were compared by
applying the Kruskal-Wallace test to the data. Because
only two mice from each strain were compared to each of
two mock infected mice, the smallest p-value obtainable
using the Kruskal-Wallace test is 0.004. Yet, the results
revealed 444 genes that showed significant differences
among strains (p ≤ 0.05). The most significant 51 genes (p
< .022) are shown in Figure 2. For each strain, the repre-
sentative spots reveal a pattern that is quite distinct from
the other two strains. The identified alterations in gene
expression that differed between strains may represent
genes that are involved with or perhaps even the basis forBMC Genomics 2006, 7:114 http://www.biomedcentral.com/1471-2164/7/114
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strain-specific degenerative processes in the brain. While
additional studies with increased sample numbers are
warranted to determine the reproducibility of these strain-
specific findings, these results demonstrate that strains of
scrapie used to inoculate mice can be distinguished based
on the expression pattern produced by differentially
expressed genes. These findings are supported by findings
of Booth et al., who used a different set of mouse scrapie
strains than the ones used in our studies and similarly
found distinct strain-specific scrapie-associated gene
expression patterns [10].
Confirmation of DNA microarray results
As an internal control, our DNA microarrays contained
several genes that have previously been shown to be
altered in the brain during mouse scrapie infection includ-
ing apolipoproteins E and D, glial fibrillary acidic protein
(GFAP),  SNAP-25, and Beta-2-microglobulin
[18,20,24,26]. Negative control genes were also included
in our arrays, including actin-b, and three plant genes:
CAB, RCA and rbcl  (Stratagene). Each of these control
genes showed the expected scrapie-associated change or
lack of change in gene expression. We also confirmed a
subset of scrapie-associated alterations identified in our
microarray studies using quantitative real time RT-PCR.
The genes we evaluated included diazepam binding
inhibitor, chemokine (C-X3-C) receptor 1, CD9 antigen,
ATPase Na+/K+ transporting beta 1 polypeptide, cathep-
sin B, glial fibrillary acidic protein, and apolipoprotein E.
Actin and Gapdh were included as negative controls. The
results of the real-time PCR are presented in Table 3. We
also sequenced nearly 400 of the cDNA clones that
showed scrapie-associated alterations in our study. In
instances where our sequencing results conflicted with
BMAP sequences reported in GenBank, the GenBank
accession number for the BMAP clone is struck through
and the gene encoded by our sequencing is listed in addi-
tional file 1, Table 1, and Table 2.
Conclusion
We identified alterations in gene expression that occur in
the brains of mice infected with scrapie strains ME7, 22L,
and RML-Chandler at two times post infection. While it is
difficult to compare our results with other previously per-
formed gene expression studies in related TSE systems,
because of the multiple differences in the methodologies
used, the considerable overlap in the genes identified in
our study and those identified in previous studies validate
the importance of these alterations in gene expression in
scrapie and suggest that these genes may generally play
important roles in TSEs.
We identified for the first time novel scrapie-associated
alterations in expression in numerous genes with known
and as of yet unknown function. Many of the identified
alterations in brain gene expression are likely important
contributors to disease. In support of this notion, Klein et
al., showed that complement gene knock out mice are
resistant to intraperitoneal but not intracerebral inocula-
tion of scrapie indicating that a single gene can be impor-
tant to early events in peripheral transmission,
propagation, and dissemination of scrapie in mice [33].
There are several genes identified in our studies that stand
out as likely cofactors in TSE pathogenesis. For example, a
large percentage of the genes we identified function in the
endosome/lysosome system. These genes are of particular
interest because the conversion of PrPc to PrPsc is thought
to occur on the cell membrane or in the endosome/lyso-
some system and PrPsc accumulates in endosomes and lys-
osomes of brain cells [34-37]. Over twenty percent of the
scrapie-associated alterations identified in our study
encode proteins that function in protein folding, protein
degradation or localize to the endosomes/lysosomes sys-
tem. We hypothesize that many of these genes are cofac-
tors in prion protein misfolding and accumulation.
Other important scrapie-associated alterations identified
in this study include genes that function in immunity,
neuronal synapses, metal ion binding, calcium regula-
tion, mitochondria and the cytoskeleton. Alterations in
immunity genes are likely largely associated with micro-
glial and astrocyte activation. Alterations in synapse genes
may be important factors in the degeneration of neuronal
dendrites. Many of the genes identified in this study bind
metal ions, consistent with a role for disruption of metal
ion homeostasis in scrapie neuropathogenesis. Altera-
tions in genes that function in calcium homoeostasis and
the mitochondria may be important factors in the degen-
eration of neurons, as maintenance of calcium homeosta-
sis and energy production is critical for neuronal survival.
Cytoskeleton gene alterations are likely reflective of
migration of microglia, but may also be factors in other
changes in cellular activity important to prion diseases
such as vacuole formation in neurons.
C57Bl mice infected intracerebrally with scrapie strains
ME7, 22L and RML-Chandler have similar time courses of
disease and develop clinical symptoms within a week of
each other at approximately 140 dpi. However, mice
infected with these three strains of scrapie differ in the
extent and localization of vacuolization and plaque forma-
tion. The intensity of vacuolation is highest in the anterior
of the brain in mice infected with ME7, similar in various
brain regions with RML-Chandler, and highest in the pos-
terior of the brain with strain 22L. Strain 22L also shows a
unique brain pathology in that it induces vacuolation in
the cerebellar cortex and the vacuoles are larger in size
compared to those induced by other strains of scrapie
[29,31,32]. Strain specific alterations in gene expression BMC Genomics 2006, 7:114 http://www.biomedcentral.com/1471-2164/7/114
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Distinct patterns of alterations in gene expression produced by mouse scrapie strains ME7, 22L, and RML-Chandler Figure 2
Distinct patterns of alterations in gene expression produced by mouse scrapie strains ME7, 22L, and RML-
Chandler. In this Cluster and TreeView representation of genes that differed significantly between strains, sample information 
is listed across the top. Each scrapie-infected mouse was compared to each of two mock-infected mice resulting in four hybrid-
izations per strain (1a–4b). Replicate results are indicated as 1b–4b. GenBank accession numbers and gene symbols are indi-
cated. Note the distinct patterns of altered gene expression between the three strains.BMC Genomics 2006, 7:114 http://www.biomedcentral.com/1471-2164/7/114
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detected in this study may indicate genes that contribute to
the molecular mechanisms underlying strain specific neu-
ropathology. However, from this study we can't distin-
guish alterations in gene expression between strains that
are due to differences in neuropathology and those due to
mice being at slightly differently stages of infection. In
future experiments we hope to better understand the proc-
ess of vacuolization by the analysis of regional expression
of genes identified as strain-specific in our studies at mul-
tiple time-points post infection using in situ hybridization
and immunohistochemical approaches.
Analysis of the cellular localization of the known genes
showed that over 40 genes encode extracellular proteins
(indicated with an asterisk in Table 1, Table 2 and addi-
tional file 1). If in future studies these proteins show TSE-
specific differential accumulation in the cerebrospinal
fluid or other accessible tissues, they could provide novel
ante-mortem diagnostic markers for TSEs using simple
antibody based or enzyme detection assays.
The studies reported here add to the handful of previously
reported gene profiling studies of TSE pathogenesis using
DNA microarrays. Our study included analysis of scrapie
strain 22L which has not previously been reported in gene
expression profiling studies, and implemented refined
microarray analysis methodologies that allowed for iden-
tification of significant disease-associated alterations in
gene expression using minimal numbers of mice. These
studies are important because they shed light on the
molecular mechanisms underlying TSE pathogenesis,
identify potential surrogate markers for TSE diagnosis,
and identify potential targets for drug treatment for TSEs.
However, information gleaned from these studies repre-
sents just the tip of the iceberg of all of the genomic and
other cellular and molecular changes that occur during
TSEs. Additional studies are needed in order to unravel the
rest of the mystery. The strain specific as well as strain
non-specific alterations in gene expression identified in
this study need to be evaluated using in situ hybridization
and immunohistochemical approaches at multiple times
post infection in order to determine the cell types in
which alterations occur, the precise time post infection
that they occur, and to determine whether specific TSE
pathology including PrPsc accumulation is associated with
cellular populations showing alterations in gene expres-
sion. In addition, studies are needed to investigate gene
expression changes in animals and humans infected with
TSEs that have different genetic backgrounds including
different alleles of PrP. Indeed Booth et al., found differ-
ences in alterations in gene expression in C57Bl/6 mice
compared to VM mice infected with scrapie strain 22A
[10]. Genomic studies in TSEs have thus far been confined
to brain and need to be expanded to other tissues such as
spleen and blood. Gene knock-out studies are needed to
determine the extent to which each of the TSE-associated
alterations in gene expression contributes to PrPsc forma-
tion, and disease pathogenesis and progression. Cross-
species studies are needed to determine alterations that
are species specific and species non-specific. A compari-
son to other infectious and neurodegenerative diseases is
needed to establish TSE-specific alterations from non-spe-
cific alterations. Studies are also needed to evaluate the
use of genomic changes as surrogate markers for disease
diagnosis, as well as the targeting genomic changes for
potential drug therapies to treat TSEs. Thus, the scrapie-
associated alterations in gene expression identified in the
studies presented here and in those previously described
have taken an important step in furthering our under-
standing the molecular mechanisms underlying TSE dis-
ease pathogenesis and disease progression. These
discoveries provide a foundation for future studies that
will take the next steps towards fully understanding TSEs,
developing novel genomic based diagnostic assays for
TSEs, and identifying targets for drug therapies to treat
TSEs.
Table 3: Real-time RT-PCR confirmation of microarray results
Encoded protein/gene Symbol Microarray fold change RT-PCR fold change* (P value)
ME7 22L RML Ave. ME7 22L RML Ave.
Diazepan binding inhibitor Dbi 1.2 1.5 1.7 1.5 2.0 (0.021) 2.2 (0.009) 1.9 (0.026) 2.0 (0.001)
CD9 antigen Cd9 1.3 1.9 1.5 1.6 2.9 (0.015) 4.2 (0.001) 3.7 (0.013) 3.6 (0.000)
CathepsinB Ctsb 1.4 1.7 1.3 1.5 1.7 (0.019) 2.0 (0.003) 1.9 (0.009) 1.9 (0.011)
Chemokine (C-X3-C) receptor 1 Cx3cr1 1.2 1.2 1.4 1.3 1.8 (0.107) 3.2 (0.025) 2.0 (0.068) 2.4 (0.011)
Atpase, Na+/K+ transporting, beta 1 Atp1b -1.6 -1.3 -1.2 -1.4 -1.3 (0.185) -1.3 (0.195) -1.3 (0.205) -1.3 (0.02)
Glial fibrillary acidic protein Gfap 4.9 11.7 4.3 6.3 11.6 (0.005) 14.6 (0.003) 12.3 (0.005) 12.8 (0.000)
Apolipoprotein E Apoe 1.9 1.8 2.0 1.9 2.2 (0.005) 2.1 (0.013) 2.7 (0.086) 2.3 (0.002)
Glyceraldehydes-3-phosphate dehydrogenase Gapdh NA NA NA NA -1.1 (0.619) -1.0 (0.798) -1.2 (0.445) -1.1 (0.393)
Actin, beta, cytoplasmic Actb 1.1 1.2 1.0 1.1 1.0 (0.829) 1.3 (0.275) 1.1 (0.693) 1.1 (0.352)
NA, not available, Gapdh not represented on microarrays
*Fold change for each strain was calculated by dividing the average mRNA level from the 2 infected animals by the average of the relative mRNA 
level of the two control animals.BMC Genomics 2006, 7:114 http://www.biomedcentral.com/1471-2164/7/114
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Methods
Scrapie infected mice
Three strains of mouse scrapie were examined: ME7, 22L,
and RML-Chandler [29,38,39]. For each strain, four male
C57BL/10 mice were inoculated intracerebrally with 50 ul
of a 1% scrapie brain homogenate from clinically affected
mice. The titer of each inocula was at least 2 ×
108infectious units/gram brain and exceeded the amount
needed to induce disease in 100% of the animals [49].
Four control male mice were mock-inoculated with 1%
homogenate of uninfected mouse brain. At 104 and 146
days post infection, two mice from each group were sacri-
ficed. Scrapie infected mice sacrificed at 146 dpi exhibited
clinical symptoms that included kyphosis, dull eyes, flat-
tened stature, weight loss and ataxia.
Preparation of microarrays
The Brain Molecular Anatomy Project (BMAP) cDNA
library [40] containing 11,136 unique cDNA clones repre-
senting 8,700 genes was purchased from Research Genet-
ics (now Invitrogen), and a largely uncharacterized 400
gene cDNA library encoding known and unknown mouse
genes developed for an unrelated project was provided by
Rashmi Korke and Wei-Shou Hu at the University of Min-
nesota for use in our microarrays. The cDNAs were ampli-
fied by PCR using primers designed from sequences of the
cloning plasmid that flanked the inserted cDNA [41] and
products analyzed on agarose gels. We were successful at
amplifying over 90% of the genes. PCR products were
purified using 96-well Millipore Multiscreen PCR cleanup
kits, resuspended in 3 × SSC to a concentration of approx-
imately 0.1 ug/g µl. DNAs were printed in duplicate onto
lysine-coated slides using a BioRobotics Microgrid II
(Genomics Solutions) DNA spotting robot. After printing,
microarrays were baked and blocked excluding rehydra-
tion as described [42]. Slide quality was evaluated using
Panomer 9-conjugated Alexa-594 dye (Molecular Probes,
now Invitrogen).
Microarray hybridization
Six scrapie-infected mice were compared to each of two
mock-infected mice at both 104 and 146 days post infec-
tion (dpi). For each timepoint a total of 12 hybridizations
was done with four hybridizations from each strain. Trizol
reagent (Invitrogen) was used to extract total brain RNA
from scrapie and mock-infected mice. RNA was reverse
transcribed, amino-allyl coupled and labeled with Cy3 or
Cy5 dyes (Molecular Probes, now Invitrogen) essentially
as described [43], using 12.5 to 25 ug of RNA. In later
experiments, 10–20% of the cDNA eluate was run on a
1% agarose gel and evaluated by spectrophotometry to
check the quality and quantity of each reaction, and sam-
ples were adjusted if needed to yield equimolar and ide-
ally at least 5 ug of labeled cDNA for experimental and
control samples. For half of the hybridizations, Cy3-
labeled cDNA from scrapie-infected mice and Cy5-labeled
cDNA from mock-infected mice were combined and
hybridized to microarrays in 40–60 ul of a solution that
contained water, 50% formamide, 5 × SSC, 0.1% SDS, 20
ug polyA, 20 ug sheared salmon sperm DNA under 25 ×
60 mm Lifterslips (Erie Scientific) in ArrayIt hybridization
chambers (TeleChem) at 42°C O/N in the dark. Half of
the hybridizations were done with the Cy3 and Cy-5 dyes
swapped between experimental and control samples. Fol-
lowing hybridization, microarrays were briefly washed
with 2 × SSC containing 0.1% SDS at 37°C, 2 × SSC at RT,
0.2 × SSC at RT, and then immediately spun dry.
Array scanning
Hybridized microarray slides were scanned with ScanAr-
ray (PerkinElmer). High powered scans were collected
such that spot intensities were as bright as possible to best
detect weakly stained spots, and low powered scans were
collected with only a small percentage of spots saturated
to best collect brightly stained spots. QuantArray (Packard
BioChip Technologies) was used to determine average
pixel values for each spot from the scanned images and to
identify poor quality spots which were not included in
these analyses. Data was exported to Microsoft Excel and
using the QuantArray QAreduce macro spot values were
normalized based on total average spot intensity and
background subtracted. To evaluate the quality of the data
from each scanned microarray, a scatter plot was created
by plotting mock verses scrapie-infected normalized and
background subtracted spot values. Variation was
observed in scatter plots from different scans of the same
hybridization and scans that yielded scatter plots that pre-
dominantly centered on a slope of one were selected for
our analyses. This selection process greatly improved the
quality of the data that was ultimately analyzed.
Statistical analyses and data mining
The first set of statistical analyses evaluated the results
from 12 microarray hybridizations at each timepoint. The
normalized and background-subtracted spot ratios from
each scan were transferred to an excel worksheet. Dupli-
cate spot ratios were moved to one row and linear spot
ratios were converted to Log2. Data from the high scans
and low scans were separately analyzed, as was data
obtained from averaging the spot ratios from the low and
the high scans. Significance Analysis of Microarrays (SAM)
with false discovery rates (FDR) and q-values were used to
identify genes that showed significant differential expres-
sion in scrapie-infected brains compared to mock-infected
brains [44,45]. A One Class Response analysis was run
with data input parameters kept at the default values. The
results from SAM analysis include a SAM score and q-
value. The SAM score is the T-statistic value. The q-value is
the lowest false discovery rate at which a gene is called sig-
nificant [45]. For example, a q-value of 1% indicates aBMC Genomics 2006, 7:114 http://www.biomedcentral.com/1471-2164/7/114
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gene has a 1% chance of being falsely identified as signif-
icant. The q-value is similar to a p-value and is the pre-
ferred measure here since the problem of multiple
comparisons makes interpretation of individual p-values
difficult. Fold change presented for each strain is the aver-
age scrapie:mock ratio of normalized and background
subtracted microarray spot values. For ease of interpreta-
tion of the data presented, fold change values less than
one were converted using the equation -1/spot ratio, e.g.
values of 0.5 were converted to -2.
To identify genes that showed scrapie-associated altera-
tions that were significantly different between strains, the
Kruskal-Wallace test was performed on data from the 146
dpi time point [46]. As a means to verify the results from
the Kruskal-Wallace test, a pairwise Wilcoxon test was per-
formed on spot ratios from ME7 vs. 22L, ME7 vs. RML,
and 22L vs. RML.
In addition, several data mining and visualization soft-
wares were used including: GeneSpring (Silicon Genet-
ics), Eisen's Cluster and Treeview [47], PathwayAssist
(Stratagene), Medline, the National Center for Biotech-
nology Information (NCBI), and the Database for Anno-
tation, Visualization, and Integrated Discovery [30].
BMAP gene annotations were updated using the Source
[48].
Quantitative real time RT-PCR
A Roche Light Cycler and Roche Light Cycler-RNA ampli-
fication kit-SYBR green I was used for quantitative real
time RT-PCR reactions. Reactions were performed in 10 ul
using 100 ng of DNAse treated total RNA. PCR primers
were designed using MacVector software (Accelrys Inc.),
and spanned introns. A stock of normal mouse brain RNA
was made, treated with DNAse, purified and used with
each RT-PCR to generate a standard curve, which was used
to verify the efficiency of RT-PCR, and as a standard to
normalize results from experimental samples. RNA from
the same eight mice used for the microarray analysis at
146 dpi was used for this analysis. The relative mRNA lev-
els were calculated using the 2-∆∆CT method using the
equation 2-(Sample CT-average of standard CT) with results from
scrapie or mock infected RNAs as the sample, and results
from normal mouse RNA amplified with same primers as
the standard [49]. The fold change was calculated using
the ratio of the average relative mRNA level from the
scrapie samples/the average relative mRNA level from the
mock-infected samples. PCR products were run on a 4%
low melt agarose gel to verify the size of product. For each
gene studied, a t-test was performed on the log of the rel-
ative mRNA levels of the target samples to verify the sig-
nificance of the results. Similar to the microarray results,
fold change values of less than 1 were converted using the
equation -1/fold change, for ease of interpretation.
Sequence verification
Plasmids were purified from BMAP and Rashmi Korke's
bacterial stocks using Qiagen QIAprep spin miniprep kits
and were sequenced at the UMN Advanced Genetics Anal-
ysis Center. The same primers used for PCR were used for
sequencing. Blast2 analysis determined whether the
sequence of cDNA clones used in our studies matched the
reported BMAP GenBank sequences [50]. In instances
where our sequencing results did not match the reported
BMAP sequence, a BLASTn search was performed to iden-
tify homologous sequences.
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